Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board of Directors
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Cellvation’s Executive Chairman, Dr. Rosenwald is Chairman and CEO of Fortress Biotech, Cellvation’s parent company, and a member of Fortress’ Board of Directors. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm that is affiliated with Fortress. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.
Frank Taffy, J.D.
Co-Founder and Board Member
Mr. Taffy serves as a member of the Board of Directors of Cellvation, Inc., a position he has held since in October of 2016. He previously served as Cellvation’s founding President and Chief Executive Officer until September of 2021. Mr. Taffy identified the programs that formed the basis of Cellvation during his role as Entrepreneur in Residence at Fortress Biotech. Prior to Fortress, Mr. Taffy held the positions of Head (Senior Director) of Business Affairs at Forest Labs (now Allergan Plc) and Director of Corporate Development at Life Technologies (now Thermo Fisher Scientific), where he also held Board positions on behalf of the company. Mr. Taffy started his career as Counsel for Intellectual Property at The Procter and Gamble Company. He holds a B.A. in biochemistry from the University of North Texas and a J.D. from Syracuse University College of Law.
Michael Weiss
Director
Mr. Weiss is a member of Cellvation’s Board of Directors and Executive Vice Chairman, Strategic Development, of Cellvation’s parent company, Fortress Biotech, where he also serves as Co-Vice Chairman of its Board of Directors. In addition to his roles at Fortress, Mr. Weiss is Executive Chairman, President and CEO of TG Therapeutics, Inc. (NASDAQ: TGTX), a publicly traded biotechnology company that he co-founded in 2011 to focus on the acquisition, development and commercialization of drugs for the treatment of b-cell malignancies, and is Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC. Previously, Mr. Weiss was Chairman and CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), where he led efforts to acquire and develop its lead drug Zerenex, and executed a strategic alliance for Zerenex with JT Tobacco, Inc., and Torii Pharmaceutical Co., Ltd., totaling more than $100 million. Mr. Weiss began his career as a lawyer at Cravath, Swaine & Moore LLP in New York City. He earned a J.D. from Columbia University Law School and a B.S. in finance from The State University of New York at Albany.